The Insightful Corner Hub
Medical Intelligence · Est. 2012
Epidemiology
Peer-reviewed
Open Access · CC BY 4.0
DOI: 10.55492/tich.2026.wast

Wastewater surveillance for H5N1: signal-to-action lag across 38 cities

A continent-scale audit of detection-to-public-health-response timelines, with a reproducible Bayesian nowcasting pipeline.

PR
Dr. Priya Raman, DrPH
Public Health Informatics · ORCID 0000-0002-28123-456X
Medically reviewed by Dr. Hugo Martín · Last reviewed May 09, 2026 · 9 min read
Clinical overview · AI-assisted synthesis

A continent-scale audit of detection-to-public-health-response timelines, with a reproducible Bayesian nowcasting pipeline.

H5N1wastewaternowcastingpandemic preparednessBayesian
Key clinical takeaways
  • 1Median detection-to-action lag was 9 days across 38 cities (IQR 4–17).
  • 2Bayesian nowcasting reduced lag by 4.2 days versus syndromic surveillance.
  • 3Cities with integrated genomic + wastewater pipelines responded twice as fast.
Evidence panel
GRADE B — Moderate
Study design
Multi-city retrospective surveillance audit
Participants
38
Studies pooled
1
Last synthesis
2026-05-09
Certainty: Moderate — methods reproducible; selection bias toward well-resourced cities.
AI synthesis model: TICH-Epi-Synth v2.4
  • · Dr. Hugo MartínEpidemiology oversight · ORCID 0000-0003-2210-5544
  • · Dr. Priya Raman, DrPHAuthor — public health informatics
Abstract

We summarize current evidence relevant to clinicians, public health officials, and policymakers. Studies were screened against PRISMA 2020; effect sizes were pooled using random-effects models with GRADE-assessed certainty.

Background

Translating evidence into bedside and population-level decisions remains uneven across health systems. This review synthesizes contemporary trials and observational data relevant to the question at hand, while flagging where uncertainty should temper recommendations.

Methods

We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov through May 2026. Two reviewers independently screened records and extracted data. Risk of bias was assessed with the Cochrane RoB 2 tool for RCTs and ROBINS-I for non-randomized studies.

Key findings

  • Pooled effect estimates were consistent in direction across pre-specified subgroups.
  • Heterogeneity (I²) was moderate at 38%, largely explained by baseline risk.
  • Number-needed-to-treat at 24 months was 41 (95% CI 32–58) for the primary outcome.

Clinical implications

For routine practice, the balance of benefits and harms favors intervention in moderate- and high-risk patients. Shared decision-making remains essential in low-risk and pediatric populations.

Limitations

Long-term safety data beyond 5 years remain sparse, and most trials were conducted in high-income settings. Generalizability to LMIC populations should be inferred with care.

Frequently asked clinical questions
Can wastewater detect H5N1 before clinical cases?

Yes — in 31 of 38 audited cities, wastewater positivity preceded the first laboratory-confirmed case by a median of 6 days.

What is the most actionable signal?

Sustained week-over-week rise in N1-segment RNA in ≥2 catchments triggered formal incident command in 28 of 38 sites.

References

  1. Okonkwo A, et al. Cardiometabolic outcomes in incretin therapy. NEJM. 2025.
  2. Raman P, et al. Wastewater nowcasting. Lancet Public Health. 2026.
  3. Asare K, et al. Pharmacist-led stewardship. BMJ. 2024.